This is a double blind, placebo controlled clinical trial, where patients with an advanced
form of blood cancer are treated with haploidentical allogeneic peripheral blood progenitor
cell (PBPC) transplant after which they are randomised to receive either placebo or a
keratinocyte growth factor (Palifermin or Kepivance®).
The function of Kepivance® is to stimulate the growth of epithelial cells. This drug has also
been suggested to have an ability to help improve the reconstitution, or development, of the
immune system after the transplantation.
The hypothesis is that the patients T-cell dependent humoral immune response to recall
antigen (PrevenarTM) will be higher in in palifermin treated patients than in the placebo
control group
Phase:
Phase 2
Details
Lead Sponsor:
European Group for Blood and Marrow Transplantation European Society for Blood and Marrow Transplantation